Levodopa responsive freezing of gait is associated with reduced norepinephrine transporter binding in Parkinson's disease

[1]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[2]  M. Hallett,et al.  Discussion of Research Priorities for Gait Disorders in Parkinson's Disease , 2021, Movement disorders : official journal of the Movement Disorder Society.

[3]  S. Bouret,et al.  Locus coeruleus neurons encode the subjective difficulty of triggering and executing actions , 2021, PLoS biology.

[4]  S. Factor,et al.  Cerebrospinal fluid biomarkers in Parkinson’s disease with freezing of gait: an exploratory analysis , 2021, npj Parkinson's Disease.

[5]  W. Cheng,et al.  Locus Coeruleus Degeneration Correlated with Levodopa Resistance in Parkinson’s Disease: A Retrospective Analysis , 2021, Journal of Parkinson's disease.

[6]  C. Cavada,et al.  Distribution of the Noradrenaline Innervation and Adrenoceptors in the Macaque Monkey Thalamus , 2021, Cerebral cortex.

[7]  A. Nieuwboer,et al.  Thalamic morphology predicts the onset of freezing of gait in Parkinson’s disease , 2021, NPJ Parkinson's disease.

[8]  Rachel P. Tillage,et al.  Co-released Norepinephrine and Galanin Act on Different Timescales to Promote Stress-Induced Anxiety-Like Behavior , 2020, bioRxiv.

[9]  N. Bamford,et al.  Propranolol Relieves L-Dopa-Induced Dyskinesia in Parkinsonian Mice , 2020, Brain sciences.

[10]  A. Pickering,et al.  Anatomically and functionally distinct locus coeruleus efferents mediate opposing effects on anxiety-like behavior , 2020, Neurobiology of Stress.

[11]  Rachel P. Tillage,et al.  Central norepinephrine transmission is required for stress-induced repetitive behavior in two rodent models of obsessive-compulsive disorder , 2019, Psychopharmacology.

[12]  S. Factor,et al.  Freezing of Gait can persist after an acute levodopa challenge in Parkinson’s disease , 2019, npj Parkinson's Disease.

[13]  Y. Shih,et al.  Noradrenergic dysfunction accelerates LPS-elicited inflammation-related ascending sequential neurodegeneration and deficits in non-motor/motor functions , 2019, Brain, Behavior, and Immunity.

[14]  R. Albin,et al.  Cholinergic system changes of falls and freezing of gait in Parkinson's disease , 2019, Annals of neurology.

[15]  J. Tran-Gia,et al.  PET imaging of noradrenaline transporters in Parkinson’s disease: focus on scan time , 2018, Annals of Nuclear Medicine.

[16]  Julie M. Hall,et al.  The functional network signature of heterogeneity in freezing of gait , 2018, Brain : a journal of neurology.

[17]  D. Weinshenker.  Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease , 2018, Trends in Neurosciences.

[18]  Moran Gilat,et al.  Dysfunctional Limbic Circuitry Underlying Freezing of Gait in Parkinson’s Disease , 2018, Neuroscience.

[19]  S. Lewis,et al.  Anxiety is associated with freezing of gait and attentional set-shifting in Parkinson's disease: A new perspective for early intervention. , 2016, Gait & posture.

[20]  Jie Wang,et al.  Alterations of functional and structural connectivity of freezing of gait in Parkinson’s disease , 2016, Journal of Neurology.

[21]  J. Votaw,et al.  Compartmental modeling of [(11)C]MENET binding to the norepinephrine transporter in the healthy human brain. , 2016, Nuclear medicine and biology.

[22]  S. Muramatsu,et al.  Freezing of Gait in Parkinson's Disease Is Associated with Reduced 6-[18F]Fluoro-l-m-tyrosine Uptake in the Locus Coeruleus , 2016, Parkinson's disease.

[23]  James M Shine,et al.  The Next Step , 2016, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[24]  G. Stebbins,et al.  Failing as doorman and disc jockey at the same time: Amygdalar dysfunction in Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.

[25]  Wei Zhang,et al.  Lifespan anxiety is reflected in human amygdala cortical connectivity , 2015, Human brain mapping.

[26]  S. Kautz,et al.  Pilot study of atomoxetine in patients with Parkinson’s disease and dopa-unresponsive Freezing of Gait , 2015, Translational Neurodegeneration.

[27]  N. Cairns,et al.  Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease , 2015, Annals of clinical and translational neurology.

[28]  J. McCall,et al.  CRH Engagement of the Locus Coeruleus Noradrenergic System Mediates Stress-Induced Anxiety , 2015, Neuron.

[29]  C. Barnum,et al.  Effects of the beta‐adrenergic receptor antagonist Propranolol on dyskinesia and L‐DOPA‐induced striatal DA efflux in the hemi‐parkinsonian rat , 2015, Journal of neurochemistry.

[30]  O. Levin,et al.  [Gait disorders in Parkinson's disease]. , 2015, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[31]  H. Berendse,et al.  A smaller amygdala is associated with anxiety in Parkinson’s disease: a combined FreeSurfer—VBM study , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[32]  Colin G. Ellard,et al.  Does Anxiety Cause Freezing of Gait in Parkinson's Disease? , 2014, PloS one.

[33]  A. Destée,et al.  Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease. , 2014, JAMA neurology.

[34]  Robert A Koeppe,et al.  Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease. , 2013, Brain : a journal of neurology.

[35]  Brett W Fling,et al.  Asymmetric pedunculopontine network connectivity in parkinsonian patients with freezing of gait. , 2013, Brain : a journal of neurology.

[36]  Oliver Speck,et al.  Cortical thickness determination of the human brain using high resolution 3T and 7T MRI data , 2013, NeuroImage.

[37]  J. Shine,et al.  Exploring the cortical and subcortical functional magnetic resonance imaging changes associated with freezing in Parkinson's disease. , 2013, Brain : a journal of neurology.

[38]  S. Sakoda,et al.  L-threo-3,4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson's disease. , 2013, Medical hypotheses.

[39]  S. Kish,et al.  Thalamic noradrenaline in Parkinson's disease: Deficits suggest role in motor and non‐motor symptoms , 2012, Movement disorders : official journal of the Movement Disorder Society.

[40]  L. Defebvre,et al.  Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial , 2012, The Lancet Neurology.

[41]  A. Bentivoglio,et al.  Nigro-striatal involvement in primary progressive freezing gait: insights into a heterogeneous pathogenesis. , 2012, Parkinsonism & related disorders.

[42]  Peter A LeWitt,et al.  Norepinephrine: the next therapeutics frontier for Parkinson's disease , 2012, Translational Neurodegeneration.

[43]  M. Hallett,et al.  Freezing of gait: moving forward on a mysterious clinical phenomenon , 2011, The Lancet Neurology.

[44]  C. Barnum,et al.  Behavioral and Cellular Modulation of l-DOPA-Induced Dyskinesia by β-Adrenoceptor Blockade in the 6-Hydroxydopamine-Lesioned Rat , 2011, Journal of Pharmacology and Experimental Therapeutics.

[45]  M. Heneka,et al.  Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits , 2010, Neurochemistry International.

[46]  W. Marchand.  Cortico-basal ganglia circuitry: a review of key research and implications for functional connectivity studies of mood and anxiety disorders , 2010, Brain Structure and Function.

[47]  F. Kirchhoff,et al.  Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine , 2010, Proceedings of the National Academy of Sciences.

[48]  Eduardo E. Benarroch,et al.  The locus ceruleus norepinephrine system , 2009, Neurology.

[49]  J. Jankovic.  Atomoxetine for freezing of gait in Parkinson disease , 2009, Journal of the Neurological Sciences.

[50]  S. Lewis,et al.  A pathophysiological model of freezing of gait in Parkinson's disease. , 2009, Parkinsonism & related disorders.

[51]  G. Miller,et al.  Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice , 2007, Proceedings of the National Academy of Sciences.

[52]  K. Rommelfanger,et al.  Norepinephrine: The redheaded stepchild of Parkinson's disease. , 2007, Biochemical pharmacology.

[53]  Ronald Boellaard,et al.  Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner , 2007, Physics in medicine and biology.

[54]  L. Porrino,et al.  Distribution of norepinephrine transporters in the non-human primate brain , 2006, Neuroscience.

[55]  Jeffrey M. Hausdorff,et al.  The role of mental function in the pathogenesis of freezing of gait in Parkinson's disease , 2006, Journal of the Neurological Sciences.

[56]  R. P. Maguire,et al.  Striatal dopa and glucose metabolism in PD patients with freezing of gait , 2006, Movement disorders : official journal of the Movement Disorder Society.

[57]  S. Factor,et al.  Primary progressive freezing gait: A syndrome with many causes , 2006, Neurology.

[58]  A. Krygowska-Wajs,et al.  Falls in Parkinson's disease. Causes and impact on patients' quality of life. , 2005, Functional neurology.

[59]  Jonathan D. Cohen,et al.  An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. , 2005, Annual review of neuroscience.

[60]  Yu-Shin Ding,et al.  Comparative evaluation of positron emission tomography radiotracers for imaging the norepinephrine transporter: (S,S) and (R,R) enantiomers of reboxetine analogs ([11C]methylreboxetine, 3‐Cl‐[11C]methylreboxetine and [18F]fluororeboxetine), (R)‐[11C]nisoxetine, [11C]oxaprotiline and [11C]lortalamine , 2005, Journal of neurochemistry.

[61]  Nora Turjanski,et al.  Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. , 2005, Brain : a journal of neurology.

[62]  G. Miller,et al.  Reduced MPTP toxicity in noradrenaline transporter knockout mice , 2004, Journal of neurochemistry.

[63]  Michel Panisset,et al.  Freezing of gait in Parkinson's disease. , 2004, Neurologic clinics.

[64]  B. Gulyás,et al.  Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (S,S)-[11C]MeNER. , 2003, Nuclear medicine and biology.

[65]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[66]  Chris Zarow,et al.  Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. , 2003, Archives of neurology.

[67]  Nikolaus R. McFarland,et al.  Thalamic Relay Nuclei of the Basal Ganglia Form Both Reciprocal and Nonreciprocal Cortical Connections, Linking Multiple Frontal Cortical Areas , 2002, The Journal of Neuroscience.

[68]  Udo Rüb,et al.  Where Does Parkinson Disease Pathology Begin in the Brain? , 2002, Journal of neuropathology and experimental neurology.

[69]  N. Tzourio-Mazoyer,et al.  Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.

[70]  Y. Agid,et al.  Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease , 2001, Movement disorders : official journal of the Movement Disorder Society.

[71]  Nikolaus R. McFarland,et al.  Organization of thalamostriatal terminals from the ventral motor nuclei in the macaque , 2001, The Journal of comparative neurology.

[72]  M. Yamamoto,et al.  Result of long-term administration of L-threo-3,4-dihydroxyphenylserine in patients with pure akinesia as an early symptom of progressive supranuclear palsy. , 1997, Clinical neuropharmacology.

[73]  A. Oke,et al.  Three-dimensional mapping of norepinephrine and serotonin in human thalamus , 1997, Brain Research.

[74]  V. Klimek,et al.  Pharmacology and Distribution of Norepinephrine Transporters in the Human Locus Coeruleus and Raphe Nuclei , 1997, The Journal of Neuroscience.

[75]  Y. Agid,et al.  Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease , 1996, Neurology.

[76]  F. Jiménez-Jiménez,et al.  “Panic attacks” in Parkinson's disease , 1993, Acta neurologica Scandinavica.

[77]  Jacob Cohen,et al.  A power primer. , 1992, Psychological bulletin.

[78]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[79]  B. Berger,et al.  Alterations of dopaminergic and noradrenergic innervations in motor cortex in parkinson's disease , 1991, Annals of neurology.

[80]  G. Paxinos,et al.  Distribution of catecholamine uptake sites in human brain as determined by quantitative [3H] mazindol autoradiography , 1991, The Journal of comparative neurology.

[81]  A. Biegon,et al.  Autoradiographic analysis of [3H]desmethylimipramine binding in the human brain postmortem , 1988, Brain Research.

[82]  A. Oke,et al.  Lateralization of norepinephrine in human thalamus. , 1978, Science.

[83]  N. Greig,et al.  Effects of Reducing Norepinephrine Levels via DSP4 Treatment on Amyloid-β Pathology in Female Rhesus Macaques (Macaca Mulatta). , 2019, Journal of Alzheimer's disease : JAD.

[84]  H. Berendse,et al.  A smaller amygdala is associated with anxiety in Parkinson’s disease – a combined FreeSurfer-Voxel-based-morphometry study , 2015 .

[85]  Sebastiaan Overeem,et al.  Gait-related cerebral alterations in patients with Parkinson's disease with freezing of gait. , 2011, Brain : a journal of neurology.

[86]  K. Oda,et al.  [PET Imaging]. , 2009, Nihon Hoshasen Gijutsu Gakkai zasshi.

[87]  Mathias Hoehn,et al.  Locus Ceruleus Degeneration Promotes Alzheimer Pathogenesis in Amyloid Precursor Protein 23 Transgenic Mice , 2006, The Journal of Neuroscience.

[88]  J. Mugler.  Overview of MR imaging pulse sequences. , 1999, Magnetic resonance imaging clinics of North America.

[89]  RockOn Team,et al.  Re: Attenuation compensation in single-photon emission tomography: a comparative evaluation. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[90]  S. Tejani-butt.  [3H]nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. , 1992, The Journal of pharmacology and experimental therapeutics.

[91]  J. Marcusson,et al.  High- and low-affinity [3H]desipramine-binding sites in human postmortem brain tissue. , 1990, Neuropsychobiology.

[92]  P N Karnauchow,et al.  Accuracy of clinical diagnosis. , 1982, Canadian Medical Association journal.

[93]  M. Spiegel-Adolf,et al.  Cerebrospinal fluid. , 1965, Progress in neurology and psychiatry.